Kato Masaki, Wakeno Masataka, Okugawa Gaku, Fukuda Tsuyoshi, Takekita Yoshiteru, Hosoi Yuka, Azuma Junichi, Kinoshita Toshihiko, Serretti Alessandro
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1041-4. doi: 10.1016/j.pnpbp.2008.01.019. Epub 2008 Feb 13.
The G-protein beta3 subunit (GNB3) gene is a key modulator of signal transduction and is a major candidate for SSRIs response. The aim of the present study is to test a possible effect of the C825T polymorphism on the antidepressant response and intolerance to selective serotonin reuptake inhibitors (SSRIs) in 146 Japanese samples with major depression treated with paroxetine or fluvoxamine for 6 weeks. The severity of depression symptom was assessed using the 21-item Hamilton Rating Scale for Depression (HAM-D) and adverse drug reactions were evaluated bi-weekly. No association with SSRIs treatment response was observed in 107 completers also including HAM-D baseline scores, SSRI type or/and 5-HTTLPR variants in the model as covariates. Furthermore, no significant association could be observed with intolerance to SSRIs in the whole subjects. The result suggests that C825T variants of GNB3 cannot play a major role as a predictor of treatment response as well as intolerance to SSRIs in Japanese patients with major depression.
G蛋白β3亚基(GNB3)基因是信号转导的关键调节因子,是选择性5-羟色胺再摄取抑制剂(SSRI)反应的主要候选基因。本研究旨在检测C825T多态性对146例接受帕罗西汀或氟伏沙明治疗6周的重度抑郁症日本患者抗抑郁反应及对SSRI不耐受的可能影响。使用21项汉密尔顿抑郁评定量表(HAM-D)评估抑郁症状的严重程度,并每两周评估一次药物不良反应。在107例完成者中未观察到与SSRI治疗反应的关联,模型中还将HAM-D基线评分、SSRI类型或/和5-HTTLPR变异作为协变量。此外,在所有受试者中未观察到与对SSRI不耐受的显著关联。结果表明,GNB3的C825T变异在重度抑郁症日本患者中,不能作为治疗反应及对SSRI不耐受的主要预测指标。